These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2974196)

  • 21. Improved renal allograft survival following donor-specific transfusions. I. Induction of antibodies that inhibit primary antidonor MLC response.
    Burlingham WJ; Sparks EM; Sondel PM; Glass NR; Belzer FO; Sollinger HW
    Transplantation; 1985 Jan; 39(1):12-7. PubMed ID: 3155578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody response and allograft outcome with deliberate donor-specific blood transfusions.
    Mendez R; Iwaki Y; Mendez RG; Bogaard T; Self B; Konoeda Y; Terasaki PI
    Transplant Proc; 1982 Jun; 14(2):378-82. PubMed ID: 7051482
    [No Abstract]   [Full Text] [Related]  

  • 23. Establishment of a human T-cell hybridoma producing an MLR suppressing factor: relationship to the mechanism of action of donor-specific transfusion.
    Haisa M; Sakagami K; Orita K
    Transplant Proc; 1990 Aug; 22(4):1977-80. PubMed ID: 2143868
    [No Abstract]   [Full Text] [Related]  

  • 24. Induction of suppressor T cells in vitro by an autologous alloreactive T cell line propagated from a DSBT-enhanced rat renal allograft.
    Ruiz P; Baldwin WM; Sanfilippo F
    Transplant Proc; 1989 Apr; 21(2):3289-91. PubMed ID: 2565616
    [No Abstract]   [Full Text] [Related]  

  • 25. Probable role of suppressor cells and factors in kidney graft survival.
    Bensussan A; Klatzmann D; Gluckman JC; Kalil J; Dausset J; Sasportes M
    Transplant Proc; 1982 Sep; 14(3):584-7. PubMed ID: 6217608
    [No Abstract]   [Full Text] [Related]  

  • 26. Significant reduction of sensitization and improved allograft outcome with donor-specific buffy coat transfusion.
    Okazaki H; Takahashi H; Miura K; Ishizaki M; Taguchi Y
    Transplantation; 1984 May; 37(5):523-5. PubMed ID: 6233767
    [No Abstract]   [Full Text] [Related]  

  • 27. Improved graft survival with donor-specific transfusion pretreatment.
    Cochrum K; Hanes D; Potter D; Perkins H; Amend W; Vincenti F; Iwaki Y; Opelz G; Terasaki P; Feduska N; Salvatierra O
    Transplant Proc; 1981 Mar; 13(1 Pt 1):190-3. PubMed ID: 7022820
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of matching for DR antigens and pretransplant blood transfusions on kidney graft survival in rhesus monkeys.
    Borleffs JC; Marquet RL; Neuhaus P
    Transplant Proc; 1982 Jun; 14(2):403-6. PubMed ID: 6214065
    [No Abstract]   [Full Text] [Related]  

  • 29. Donor-specific transfusion: a report of the Japanese Renal Transplant Registry.
    Sonoda T; Ishibashi M
    Clin Transpl; 1987; ():257-60. PubMed ID: 2978999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience of blood transfusion in renal transplantation.
    Frisk B; Berglin E; Blohmé I; Persson H; Sandberg L; Wedel N; Brynger H
    Scand J Urol Nephrol Suppl; 1984; 88():1-69. PubMed ID: 6399773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pros and cons of donor-specific blood transfusions in living related kidney transplantation.
    Sijpkens YW; Koep LJ; Persijn GG; Van der Werf BA
    Neth J Med; 1984; 27(1):1-5. PubMed ID: 6231486
    [No Abstract]   [Full Text] [Related]  

  • 32. Renal allograft recipient immunomodulation by concomitant immunosuppression and donor-specific transfusions.
    Anderson CB; Jendrisak MD; Flye MW; Hanto DW; Anderman CK; Rodey GE; Sicard GA
    Transplant Proc; 1988 Dec; 20(6):1074-8. PubMed ID: 3059589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update of the University of California at San Francisco experience with donor-specific blood transfusions.
    Salvatierra O; Iwaki Y; Vincenti F; Amend W; Terasaki P; Garovoy M; Duca R; Hopper S; Feduska N
    Transplant Proc; 1982 Jun; 14(2):363-6. PubMed ID: 7051480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretransplant blood transfusions revisited: a role for CD(4+) regulatory T cells?
    Roelen D; Brand A; Claas FH
    Transplantation; 2004 Jan; 77(1 Suppl):S26-8. PubMed ID: 14726766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Planned third-party transfusions prior to first transplantations from liver related donors.
    Brynger H; Frisk B; Larsson O; Sandberg L
    Scand J Urol Nephrol Suppl; 1981; 64():152-6. PubMed ID: 6755674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible mechanism of the beneficial effect of pretransplant blood transfusions on renal allograft survival in man.
    Singal DP; Joseph S; Szewczuk MR
    Transplant Proc; 1982 Jun; 14(2):316-8. PubMed ID: 6214059
    [No Abstract]   [Full Text] [Related]  

  • 37. Pretreatment with donor-specific blood transfusions in related recipients with high MLC.
    Salvatierra O; Amend W; Vincenti F; Potter D; Iwaki Y; Opelz G; Terasaki P; Duca R; Hanes D; Cochrum KC; Hopper S; Feduska NJ
    Transplant Proc; 1981 Mar; 13(1 Pt 1):142-9. PubMed ID: 6455788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fresh versus stored blood in donor specific transfusion.
    Light JA; Metz S; Oddenino K; Simonis T; Strong DM; Reinmuth B; Kumar J; Biggers JA
    Transplant Proc; 1982 Jun; 14(2):296-301. PubMed ID: 6214058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donor-specific CML hyporesponsiveness after successful renal transplantation: studies on the mechanism.
    Thomas JM; Thomas FT; Hoffman S; Johns C; Mendez-Picon G; Lee HM
    Transplant Proc; 1979 Jun; 11(2):1258-9. PubMed ID: 157568
    [No Abstract]   [Full Text] [Related]  

  • 40. Spleen mixed leukocyte chimerism and induction of tolerance in rat renal allograft recipients conditioned with donor-specific blood transfusions and cyclosporine.
    Llull R; Mañez R; Domenech N; Starzl TE; Black KS; Hewitt CW
    Transplant Proc; 1995 Aug; 27(4):2374-6. PubMed ID: 7652844
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.